Amylyx Pharmaceuticals Inc   (AMLX)
Other Ticker:  
Price: $18.7100 $-0.14 -0.743%
Day's High: $19.2 Week Perf: 6.55 %
Day's Low: $ 18.58 30 Day Perf: 16.94 %
Volume (M): 1,126 52 Wk High: $ 38.32
Volume (M$): $ 21,062 52 Wk Avg: $21.11
Open: $19.04 52 Wk Low: $11.82

 Market Capitalization (Millions $) 1,305
 Shares Outstanding (Millions) 70
 Employees 80
 Revenues (TTM) (Millions $) 294
 Net Income (TTM) (Millions $) 2
 Cash Flow (TTM) (Millions $) 28
 Capital Exp. (TTM) (Millions $) 2

Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc is a biopharmaceutical company that is dedicated to saving lives and improving the quality of life for people who suffer from neurodegenerative diseases. The company was founded in 2013 by a group of renowned clinicians, scientists, and entrepreneurs who were keen on addressing the severe unmet needs of patients who were suffering from diseases such as ALS, Alzheimer's, and Parkinson's.

Amylyx Pharmaceuticals is headquartered in Cambridge, Massachusetts, and it has a strong reputation as a leader in the development of treatments for neurodegenerative diseases. The company's research and development team is composed of some of the industry's most innovative and experienced scientists who have developed some of the most successful treatments for these diseases.

One of the most notable aspects of Amylyx Pharmaceuticals' approach is its focus on finding therapies that aim to treat the underlying cause of the disease rather than just the symptoms. The company's flagship product is AMX0035, which is developed as a combination of two small molecules that aim to protect and restore key cellular processes in the central nervous system.

Amylyx Pharmaceuticals has received numerous accolades for its groundbreaking work in neurodegenerative diseases. The company has been recognized by prestigious organizations such as the National Institutes of Health, the ALS Association, and the Alzheimer's Association. Amylyx Pharmaceuticals has also raised millions in funding from investors such as Morningside Ventures and the ALS Investment Fund.

The company's approach to research and development has also garnered praise from the scientific community. Amylyx Pharmaceuticals has published numerous peer-reviewed papers in top-tier journals that showcase the company's innovative approach to developing therapies for neurodegenerative diseases.

Overall, Amylyx Pharmaceuticals Inc. is a forward-thinking and innovative biopharmaceutical company that is dedicated to improving the lives of individuals afflicted with neurodegenerative diseases. With a strong focus on research and development, the company is poised to continue its exceptional progress in developing groundbreaking treatments for these devastating illnesses.

   Company Address: 43 Thorndike St. Cambridge 2141 MA
   Company Phone Number: 682-0917   Stock Exchange / Ticker: NASDAQ AMLX
   AMLX is expected to report next financial results on March 12, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc. Clinches Positive Income for July-September 2023, Reflecting Remarkable Growth

Amylyx Pharmaceuticals Inc has delivered impressive financial results, with a staggering 29666.087% year-on-year revenue increase to $102.69 million in its fiscal period ending September 30, 2023. However, despite this remarkable achievement, the company's income turned positive at only $0.30. This unexpected development raises questions about Amylyx Pharmaceuticals' future prospects and how these results will impact the company going forward.
Revenue Growth Amidst Industry Decline:
Amylyx Pharmaceuticals Inc's revenue improvement stands out in the Major Pharmaceutical Preparations sector, which has experienced a decline of -5.64% in business. While most companies in the sector struggle, Amylyx Pharmaceuticals Inc managed to grow its revenue by 4.558% from $98.22 million in the preceding reporting period. This positive growth highlights the company's resilience and ability to adapt to changing market dynamics.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc Records Impressive Revenue of $98.216 Million in Q2 2023 Financial Report, Showcasing Positive Turnaround and Improved Profitability

Amylyx Pharmaceuticals Inc has reported a revenue of $98.216 million in the second quarter of 2023. This represents a significant improvement compared to the same reporting period last year, where the company experienced a net shortfall of $-54.067 million. The net income for the second quarter of 2023 stood at $22.074 million, indicating a positive turnaround for the company.
One of the highlights of the financial report is the improving profit margins of Amylyx Pharmaceuticals Inc. The net margin for the second quarter of 2023 rose to 22.47%, reflecting an increase in profitability. Moreover, the operating margin edged up to 20.57%, showcasing the company's efficiency in managing its operational costs.


Amylyx Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com